Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?
China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.
You may also be interested in...
Shanghai is significantly tightening its grip on pharma commercial activities with two new rules in August. One restricts medical sales reps from visiting physicians outside a pre-set time and location, and another requires drug makers to register their sales reps with the local FDA.
Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.